An enhanced genetic mutation-based model for predicting the efficacy of immune checkpoint inhibitors in patients with melanoma.

导出 LinkOut

翻译打印收藏纠错

作者： Chaohu,Pan ^[1] ; Hongzhen,Tang ^[2] ; Wei,Wang ^[3] ; Dongfang,Wu ^[4] ; Haitao,Luo ^[4] ; Libin,Xu ^[4] ; Xue-Jia,Lin ^[4]

作者单位： The First Affiliated Hospital, Jinan University, Guangzhou, Guangdong, China. ^[1] Zhuhai Institute of Translational Medicine, Zhuhai People's Hospital (Zhuhai Hospital Affiliated with Jinan University), Jinan University, Zhuhai, Guangdong, China. ^[2] The Biomedical Translational Research Institute, Faculty of Medical Science, Jinan University, Guangzhou, Guangdong, China. ^[3] Department of Medicine, YuceBio Technology Co., Ltd, Shenzhen, Guangdong, China. ^[4] Department of Orthopedic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. ^[5]

关键词 durable clinical benefit model genetic mutation immune checkpoint inhibitors machine learning classifiers melanoma

DOI 10.3389/fonc.2022.1077477

PMID 36733353

发布时间 2023-02-04

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Frontiers in oncology

2022年12卷

1077477页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

An enhanced genetic mutation-based model for predicting the efficacy of immune checkpoint inhibitors in patients with melanoma.

Frontiers in oncology

相似文献

Frontiers in oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

An enhanced genetic mutation-based model for predicting the efficacy of immune checkpoint inhibitors in patients with melanoma.

Frontiers in oncology

相似文献

Frontiers in oncology

相关期刊

检索历史清除